文献速递妇科

新辅助化疗调控高级别浆液性癌的肥大细胞表型与免疫浸润

Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma.
PubMed 文献 · Gynecol Oncol · 2025-11-01

本研究通过本院RNA测序(新辅助化疗前8例、后7例肿瘤样本)、三个GEO数据集及73对化疗前后免疫组化,分析高级别浆液性癌新辅助化疗前后免疫浸润差异。新辅助化疗后CD8+ T细胞与肥大细胞浸润增加,KIT表达升高尤其见于应答者且与不良预后相关,CD52+KIT+肥大细胞向JUN+/TNFRSF12A+亚群转变。

要点

  • 新辅助化疗后高级别浆液性癌组织CD8+ T细胞与肥大细胞浸润增加。
  • 化疗后KIT表达升高,尤其在应答者中,且KIT高表达与不良预后相关。
  • 化疗后CD52+KIT+肥大细胞减少,JUN+/TNFRSF12A+亚群增加。

核心结论

  • 成功的新辅助化疗与CD52+KIT+肥大细胞减少及JUN+/TNFRSF12A+亚群增加相关。
  • 表达KIT的肥大细胞浸润增加可能作为新辅助化疗后高级别浆液性癌的预后生物标志物,并可能是增强新辅助化疗疗效的潜在新治疗靶点。

研究设计与样本

  • 研究分析新辅助化疗前后高级别浆液性癌组织的免疫浸润模式,使用本院RNA测序数据(新辅助化疗前8例、后7例肿瘤样本)、三个GEO数据集(GSE181597、GSE201600、GSE227666)及73对新辅助化疗前后样本的免疫组化。
  • 新辅助化疗反应采用化疗反应评分(CRS)评估,分为应答者(CRS=3)和非应答者(CRS=1/2)。
  • 利用单细胞RNA测序数据(GSE165897)进行Scissor和拟时序分析,研究肥大细胞表型相关细胞群及发育轨迹。

主要发现

  • 新辅助化疗引发免疫细胞浸润的动态变化,以CD8+ T细胞和肥大细胞浸润增加为特征,并经免疫组化证实。
  • 新辅助化疗后KIT表达显著增加,尤其在应答者中;而新辅助化疗前应答者与非应答者之间未检测到显著差异。
  • KIT表达升高与不良预后相关。
  • 新辅助化疗后发生从CD52+KIT+肥大细胞向JUN+/TNFRSF12A+亚群的转变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The influence of neoadjuvant chemotherapy (NACT) on the immune landscape of high-grade serous carcinoma (HGSC) remains inadequately understood. This study aims to investigate the differential patterns of immune infiltration in HGSC tissues before and after NACT, as well as their clinical significance. METHODS: Immune infiltration patterns in HGSC tissues pre- and post-NACT were analyzed using our in-house RNA sequencing data (comprising 8 pre-NACT and 7 post-NACT tumor samples), three GEO datasets (GSE181597, GSE201600, GSE227666), and immunohistochemistry on 73 paired pre- and post-NACT samples. The response to NACT was evaluated using the Chemotherapy response score (CRS), categorizing patients as responders (CRS = 3) and non-responders (CRS = 1/2). Scissor and pseudotime analyses were conducted to investigate mast cell phenotype-associated cell populations and developmental trajectories utilizing single-cell RNA sequencing data (GSE165897). RESULTS: NACT prompted dynamic alterations in immune cell infiltration, notably characterized by an increase in CD8+ T cells and mast cell infiltration, which were corroborated by immunohistochemistry. Following NACT, there was a notable increase in KIT expression, particularly among responders, whereas no significant difference was detected between responders and non-responders prior to NACT. Elevated KIT expression was linked to a poor prognosis. There was a transition from CD52 + KIT+ mast cells to JUN+/TNFRSF12A+ subsets post-NACT. CONCLUSIONS: Successful NACT was associated with a reduction in CD52 + KIT+ mast cells and an increase in the JUN+/TNFRSF12A+ subpopulation. The increased infiltration of KIT-expressing mast cells may serve as a prognostic biomarker for HGSC following NACT and represent a potential novel therapeutic target to enhance NACT efficacy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fan Y, Wang Q, Deng H, et al. Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma. Gynecol Oncol. 2025. PMID: 41176887. doi:10.1016/j.ygyno.2025.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。